Immunization of pregnant women: reproductive, medical and societal risks

• Published in: Vaccine 2003-07, Vol.21 (24), p.3413-3421
• Main Author: Brent, Robert L.
• Format: Article
• Language: English
• Subjects: Abortion; Adult; Biological and medical sciences; Birth defects; Births; Cell adhesion & migration; Cytomegalovirus; Defects; Diabetes; Embryos; Encephalitis; Female; Fetus - immunology; Fetuses; Food contamination; Fundamental and applied biological sciences. Psychology; Genetic disorders; Hepatitis; Humans; Immunization; Immunization - adverse effects; Infant, Newborn; Infections; Infectious diseases; Infertility; Infertility, Female - immunology; Litigation; Mother. Fetoplacental unit. Mammary gland. Milk; Negligence; Negligence litigation; Neonatal infections; Pregnancy; Pregnancy - immunology; Pregnancy. Parturition. Lactation; Premature labor; Prematurity; Prescription drugs; Risk Assessment; Teratogens - toxicity; Vaccines; Vaccines - immunology; Vaccines - toxicity; Vertebrates: reproduction; Womens health
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/S0264-410X(03)00396-7

Establishing successful vaccine programs for pregnant women would be the quintessence of preventive medicine when you realize the preventive potential for reproductive problems of many of the new and old vaccines. The development of vaccines to prevent maternal, fetal and newborn disease is actually in its infancy. The risks and benefits are discussed in detail as well as the most appropriate and inappropriate time to immunize women of reproductive age and pregnant women. The great majority of risks are theoretical, but the problem is that birth defects and other developmental and reproductive problems are in the group of “diseases of affliction” which means that there are tremendous emotional upheavals in families affected with serious reproductive problems. The failures in reproduction are so common that immunization of a pregnant women has potential deleterious consequences. A consortium of government, academia and industry must work together and an appeal to the more responsible members of the law profession to solve the problem of non-meritorious litigation has be in place before manufacturers of vaccines will be willing to initiate the development of new vaccines. The potential for reducing the incidence of birth defects, prematurity and neonatal infectious disease exists, but it will be difficult to initiate these programs because vaccine makers may be unwilling to assume an additional burden of negligence litigation. Certainly, it is clear that we could provide a safe vaccine for Group B streptococcus and infant botulism that would be of immediate benefit and the potential for reducing other diseases is realistic. This is not going to be an easy task.